Edition:
United States

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

5.72USD
20 Jul 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.72
Open
$5.70
Day's High
$5.74
Day's Low
$5.58
Volume
19,992
Avg. Vol
79,946
52-wk High
$13.05
52-wk Low
$4.78

Chart for

About

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product... (more)

Overall

Beta: -0.88
Market Cap(Mil.): $117.30
Shares Outstanding(Mil.): 20.51
Dividend: --
Yield (%): --

Financials

  REPH.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -2.43 -- --
ROI: -31.35 -3.65 13.18
ROE: -104.68 -5.62 15.09

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

May 24 2018

UPDATE 2-Recro Pharma shares plummet after FDA rejects non-opioid pain shot

* FDA says drug's pain-relieving effect did not meet expectations

May 24 2018

BRIEF-Recro Pharma Receives Complete Response Letter From FDA

* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA

May 24 2018

FDA declines to approve Recro Pharma's non-opioid pain shot

The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.

May 24 2018

BRIEF-Recro Pharma Reports Q1 Loss Per Share Of $0.65

* Q1 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S

May 09 2018

BRIEF-Recro Pharma Announces Receipt Of Issue Notifications For Three New Patents For Iv Meloxicam

* RECRO PHARMA ANNOUNCES RECEIPT OF ISSUE NOTIFICATIONS FOR THREE NEW PATENTS FOR IV MELOXICAM Source text for Eikon: Further company coverage:

May 07 2018

BRIEF-Recro Pharma Inc Reports Year End 2017 Financial Results

* RECRO PHARMA INC - FOR 2018, COMPANY EXPECTS REVENUE GENERATED FROM ITS CDMO DIVISION TO BE APPROXIMATELY $70 MILLION

Feb 27 2018

BRIEF-Recro Pharma Estimates Cash And Cash Equivalents About $64 Mln As Of Dec 31

* RECRO PHARMA - ESTIMATES THAT AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $64.0 MILLION Source text for Eikon: (http://bit.ly/2nOPGN7) Further company coverage:

Feb 07 2018

Earnings vs. Estimates